14. September 2012:  The Board of Directors of NORDA has during the summer reviewed the company's strategy and files today an application for continued listing at Oslo Stock Exchange, OB Match.

NORDA ASA will continue to invest in the Life Science sector;

• Develop Genefec for international licensing.
• Acquire ownership in related life science technologies with international licensing potential.
• Expand the Swedish service and supply contracts to include other laboratory instruments.

The company plans to raise capital to execute its strategy. Going forward, the company will implement a more efficient long term financial strategy implying larger, but less frequent share issues to fund its investments. Surplus liquidity will be invested in financial instruments; equities and bonds.

For further information, contact :
Managing director Hans Hekland, phone: +47 906 26 870

Read the notice in Norwegian here.